Twitter Use in the Hematopoietic Cell Transplantation Community.

abstract：:Mycosis fungoides (MF) and its leukemic variant, Sézary syndrome (SS), are malignancies of skin-homing T cells that comprise the majority of cutaneous T cell lymphomas (CTCL). Treatment of CTCL is limited and can be approached by skin-directed therapy or systemic therapy. Recent investigations into the pathogenesis of...

journal_title：Current hematologic malignancy reports

authors： Chung CG,Poligone B

更新日期：2015-12-01 00:00:00

abstract：PURPOSE OF REVIEW:Novel immunotherapies such as checkpoint inhibitors, bispecific antibodies, and chimeric antigen receptor T cells are leading to promising responses when treating solid tumors and hematological malignancies. T cell neoplasms include leukemia and lymphomas that are derived from T cells and overall are ...

journal_title：Current hematologic malignancy reports

authors： Ghione P,Moskowitz AJ,De Paola NEK,Horwitz SM,Ruella M

更新日期：2018-12-01 00:00:00

abstract：PURPOSE OF REVIEW:In this review article, we will highlight ethical issues faced by hematologists due to a growing constellation of expensive diagnostics and therapeutics in hematology. We outline the important issues surrounding this topic including stakeholders, cost considerations, and various ethical challenges sur...

journal_title：Current hematologic malignancy reports

authors： Ertz-Archambault N,Khera N

更新日期：2020-10-01 00:00:00

abstract：:Chronic myelomonocytic leukemia is a clonal malignancy of the ageing hematopoietic stem cell characterized by a biased differentiation leading to persistent monocytosis and inconstant hypersensitivity of myeloid progenitors to granulo-monocyte colony-stimulating factor (GM-CSF). Cytogenetic abnormalities identified in...

journal_title：Current hematologic malignancy reports

authors： Selimoglu-Buet D,Solary E

更新日期：2014-12-01 00:00:00

abstract：PURPOSE OF REVIEW:Antibody-drug conjugates are a new class of therapeutic agents in the treatment of B cell malignancies. In this review, we summarize the recent developments of polatuzumab vedotin in the treatment of relapsed or refractory diffuse large B cell lymphoma (DLBCL) and follicular lymphoma (FL). RECENT FIN...

journal_title：Current hematologic malignancy reports

authors： Choi Y,Diefenbach CS

更新日期：2020-04-01 00:00:00

abstract：:A high risk of arterial and venous thrombosis is the hallmark of chronic myeloproliferative neoplasms (MPNs), particularly polycythemia vera (PV) and essential thrombocythemia (ET). Clinical aspects, pathogenesis and management of thrombosis in MPN resemble those of other paradigmatic vascular diseases. The occurrence...

journal_title：Current hematologic malignancy reports

authors： Finazzi G,De Stefano V,Barbui T

更新日期：2013-12-01 00:00:00

abstract：PURPOSE OF REVIEW:Over the past two decades, the introduction of tyrosine kinase inhibitors (TKIs) has transformed the treatment of chronic myeloid leukemia (CML). With four agents currently approved for frontline use in chronic-phase (CP) disease, it follows that treatment decision-making has been rendered more challe...

journal_title：Current hematologic malignancy reports

authors： Kennedy JA,Hobbs G

更新日期：2018-06-01 00:00:00

abstract：PURPOSE OF REVIEW:Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare malignancy derived from plasmacyoid dendritic cells whose biology, clinical features, and treatment options are increasingly better understood. RECENT FINDINGS:TCF4 is a master regulator that drives donwstream transcriptional programs in ...

journal_title：Current hematologic malignancy reports

authors： Khoury JD

更新日期：2018-12-01 00:00:00

abstract：:Follicular lymphoma (FL), the most common indolent lymphoma, typically presents in advanced-stage disease. Currently available therapy does not generally result in a curative outcome, but survival in FL has improved since the introduction of anti-CD20 monoclonal antibody immunotherapy. The goals of treatment include p...

journal_title：Current hematologic malignancy reports

authors： Forstpointner R,Dreyling M

更新日期：2011-12-01 00:00:00

abstract：:The peripheral T cell lymphomas (PTCLs) are a heterogeneous group of neoplasms for which standardized treatment approaches remain elusive. A number of new therapeutic agents have become available, of which monoclonal antibodies (MAbs) represent a powerful tool for targeted treatment of PTCLs. Therapeutic MAbs vary in ...

journal_title：Current hematologic malignancy reports

authors： Hebb J,Kohrt H

更新日期：2015-12-01 00:00:00

abstract：PURPOSE OF REVIEW:Older adults with hematologic malignancy are a growing demographic. Estimating risk of chemotherapy toxicity based on age alone is an unreliable estimate of quality of life, functional capacity, or risk of treatment complications. RECENT FINDINGS:Dedicated geriatric assessment tools can aid the clini...

journal_title：Current hematologic malignancy reports

authors： Koll TT,Rosko AE

更新日期：2018-06-01 00:00:00

abstract：:Hodgkin's lymphoma (HL) is a relatively rare disease accounting for 15 % of all lymphoma. This disease has developed from an incurable disease to the adult malignancy with the most favorable prognosis. With current therapeutic approaches consisting of polychemo- and small-field radiotherapy, up to 80 % of all patients...

journal_title：Current hematologic malignancy reports

authors： Bröckelmann PJ,Engert A

更新日期：2015-09-01 00:00:00

abstract：PURPOSE OF REVIEW:CMV DNA polymerase inhibitors such as ganciclovir and foscarnet have dramatically reduced the burden of CMV infection in the HCT recipient. However, their use is often limited by toxicities and resistance. Agents with novel mechanisms and favorable toxicity profiles are critically needed. We review re...

journal_title：Current hematologic malignancy reports

authors： Hakki M

更新日期：2020-04-01 00:00:00

abstract：:Hodgkin lymphoma (HL) is a rare malignancy of the lymphatic system that is curable in at least 80 % of patients. Although patients usually present with painless lymphadenopathy, a variety of systemic and organ-specific syndromes may also exist in relation to HL. These syndromes may develop before, during, or after the...

journal_title：Current hematologic malignancy reports

authors： Barber NA,Bierman PJ

更新日期：2012-09-01 00:00:00

abstract：:Multiple myeloma is a disorder of terminally differentiated plasma cells, characterized by immune dysfunction, deregulated signaling within the bone marrow stromal compartment, and a microenvironment that fosters immunosuppression. Immunomodulatory techniques, such as allogeneic hematopoietic stem cell transplant (all...

journal_title：Current hematologic malignancy reports

authors： Karp Leaf R,Cho HJ,Avigan D

更新日期：2015-12-01 00:00:00

abstract：:C. difficile infection (CDI), the most common cause of hospital-acquired diarrhea, is very frequent after hematopoietic stem cell transplantation (HSCT). Recent publications suggest it affects between 6 % and 20 % of HSCT recipients during the first year and is more common following allogeneic transplant (allo-HSCT). ...

journal_title：Current hematologic malignancy reports

authors： Callejas-Díaz A,Gea-Banacloche JC

更新日期：2014-03-01 00:00:00

abstract：:The introduction of imatinib represented a breakthrough in the treatment of chronic myelogenous leukemia (CML). However, about 20% of patients treated in early chronic-phase CML are off therapy after 6 years because of resistance or intolerance, and most patients taking imatinib remain BCR-ABL-positive at the molecula...

journal_title：Current hematologic malignancy reports

authors： La Rosée P,Hochhaus A

更新日期：2008-04-01 00:00:00

abstract：PURPOSE OF REVIEW:This review discusses the current standard of care for incorporation of FLT3 TKIs and HCT into the treatment of FLT3-ITD AML. Additionally, this review provides an approach to the patient with relapsed/refractory disease. RECENT FINDINGS:Over the last decade, the routine use of HCT as consolidative t...

journal_title：Current hematologic malignancy reports

authors： Hunter BD,Chen YB

更新日期：2020-02-01 00:00:00

abstract：PURPOSE OF REVIEW:Passive immunotherapy with therapeutic monoclonal antibodies (mAbs) has revolutionized the treatment of cancer, especially hematological malignancies over the last 20 years. While use of mAbs has improved outcomes, development of resistance is inevitable in most cases, hindering the long-term survival...

journal_title：Current hematologic malignancy reports

authors： Torka P,Barth M,Ferdman R,Hernandez-Ilizaliturri FJ

更新日期：2019-10-01 00:00:00

abstract：PURPOSE OF REVIEW:Ruxolitinib is the first FDA-approved JAK inhibitor for the treatment of myeloproliferative neoplasms and is an effective means of controlling symptom burden and improving splenomegaly. However, a majority of patients will develop disease progression with long-term use. Fedratinib, momelotinib, and pa...

journal_title：Current hematologic malignancy reports

authors： Patel AA,Odenike O

更新日期：2020-12-01 00:00:00

abstract：:Mantle cell lymphoma (MCL) is a unique lymphoma subtype comprising 6% to 8% of new lymphoma diagnoses. It is generally considered to be incurable with standard lymphoma therapies. The median overall survival (OS) is often reported to be 3 to 4 years, but more recent data suggest that the median OS may be longer than 5...

journal_title：Current hematologic malignancy reports

authors： Kahl BS

更新日期：2009-10-01 00:00:00

abstract：:High-dose chemotherapy with autologous stem cell transplantation (ASCT) has been shown to improve survival in patients with multiple myeloma in randomized trials and is the standard of care for eligible patients. Recent randomized trials suggest a survival benefit with tandem ASCT, notably for patients failing to achi...

journal_title：Current hematologic malignancy reports

authors： Kumar S

更新日期：2007-05-01 00:00:00

abstract：PURPOSE OF REVIEW:To discuss the impact that next-generation sequencing has had on myeloproliferative neoplasm prognosis and treatment response. RECENT FINDINGS:Extended genetic testing has led to a more comprehensive understanding of the mutational landscape in the myeloproliferative neoplasms. More refined prognosti...

journal_title：Current hematologic malignancy reports

authors： Mina AA,Stein B

更新日期：2019-06-01 00:00:00

abstract：:Chronic myeloid leukemia (CML) arises as a consequence of a chromosomal translocation giving rise to the Philadelphia chromosome and Bcr-Abl oncogene. CML is a clonal disease of stem cell origin and an excellent example of a malignancy in which tumor-initiating cells may hold the key to disease eradication. The known ...

journal_title：Current hematologic malignancy reports

authors： Helgason GV,Young GA,Holyoake TL

更新日期：2010-04-01 00:00:00

abstract：:Acute myeloid leukemia (AML) is a very heterogeneous disease. Prognosis is related not only to intrinsic characteristics such as cytogenetics and molecular markers, but also the patient's ability to tolerate therapy, and treatment response. Allogeneic stem cell transplantation (allo-HCT) has been traditionally indicat...

journal_title：Current hematologic malignancy reports

authors： Lekakis LJ,Cooper BW,de Lima MG

更新日期：2014-06-01 00:00:00

abstract：PURPOSE OF REVIEW:There are limited treatment options for relapsed/refractory classical Hodgkin lymphoma (cHL) patients who progress on brentuximab vedotin and programmed death-1 inhibitors. Camidanlumab Tesirine (Cami) is a new agent that has shown activity in multiply relapsed/refractory cHL patients. In this review,...

journal_title：Current hematologic malignancy reports

authors： Epperla N,Hamadani M

更新日期：2021-01-25 00:00:00

abstract：PURPOSE OF REVIEW:Determine if therapy of chronic myeloid leukaemia (CML) is a model for treating other cancers. RECENT FINDINGS:CML has a relatively homogeneous phenotype and genotype and is caused by one mutation, BCRABL1, in every instance. In contrast, most other leukaemias, haematologic cancers and solid cancer h...

journal_title：Current hematologic malignancy reports

authors： Gale RP,Apperley J

更新日期：2019-12-01 00:00:00

abstract：PURPOSE OF REVIEW:The use of circulating tumor DNA (ctDNA) for the purposes of diagnosis, prognosis, assessment of treatment response, and monitoring for relapse is a new and developing field in lymphoma. This review aims to summarize many of the most recent advances in ctDNA applications. RECENT FINDINGS:Recent studi...

journal_title：Current hematologic malignancy reports

authors： Darrah JM,Herrera AF

更新日期：2018-10-01 00:00:00

abstract：:Compared with acute lymphoblastic leukemia (ALL) in older children, ALL in infants has a dismal outcome because rearrangements of the mixed-lineage leukemia (MLL) gene occur in about 80% of these patients, leading to an aggressive type of leukemia. With most recent therapies, about 50% long-term event-free survival is...

journal_title：Current hematologic malignancy reports

authors： Pieters R

更新日期：2009-07-01 00:00:00

abstract：:Among the few drugs that have shown a benefit for patients with acute myeloid leukemia (AML) in randomized clinical trials over the last several decades is the CD33 antibody-drug conjugate, gemtuzumab ozogamicin (GO). Undoubtedly, this experience has highlighted the value of antigen-specific immunotherapy in AML. A wi...

journal_title：Current hematologic malignancy reports

authors： Buckley SA,Walter RB

更新日期：2015-06-01 00:00:00